Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain

Size: px
Start display at page:

Download "Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain"

Transcription

1 Vol. 25 No. 5S May 2003 Journal of Pain and Symptom Management S31 Neuropathic Pain: From Mechanisms to Treatment Strategies Rationale and Evidence for the Use of Oxcarbazepine in Neuropathic Pain Enrique Carrazana, MD and Imao Mikoshiba, PhD Neuroscience, Clinical Development and Medical Affairs (E.C.), Novartis Pharmaceuticals, East Hanover, New Jersey, USA, and Kissei Pharmaceutical Company Ltd. (I.M.), Tokyo, Japan Abstract Oxcarbazepine is a second-generation antiepileptic drug (AED) with proven efficacy in managing partial epileptic seizures, with or without secondary generalization, in adults and children. The overlap between the underlying pathophysiologic mechanisms of some epilepsy models and neuropathic pain models supports the rationale for using certain AEDs in the treatment of neuropathic pain. Several AEDs have reportedly produced analgesia in a range of neuropathic pains, including painful diabetic neuropathy (PDN) and post-herpetic neuralgia. Increasing evidence suggests that oxcarbazepine can provide significant analgesia in several neuropathic pain conditions, including trigeminal neuralgia and PDN, and is also may be effective in treating neuropathic pain refractory to other AEDs, such as carbamazepine and gabapentin. The analgesic effects of oxcarbazepine, and its generally improved safety and tolerability profile compared with other standard AEDs, suggests that oxcarbazepine will be an important addition to the neuropathic pain armamentarium. The rationale and evidence to support the efficacy of oxcarbazepine are presented here. J Pain Symptom Manage 2003; 25:S31 S U.S. Cancer Pain Relief Committee. Published by Elsevier. All rights reserved. Key Words Neuropathic pain, antiepileptic drug, oxcarbazepine, trigeminal neuralgia, refractory pain, painful diabetic neuropathy Introduction Analgesic action was first reported for an antiepileptic drug (AED) in 1942, when phenytoin was found to be effective in some patients with trigeminal neuralgia (TGN). 1 Twenty years later, Blom reported that carbamazepine was also effective in treating TGN. 2 This was subsequently confirmed in three placebo-controlled Address reprint requests to: Enrique Carrazana, MD, Neuroscience, Clinical Development and Medical Affairs, Novartis Pharmaceuticals, Building 403, Room 362, 59 Route 10, East Hanover, NJ, , USA. trials, which clearly demonstrated the efficacy of carbamazepine treatment in patients with TGN. 3 5 Carbamazepine ( mg/day) was associated with improved pain relief in 70 75% of patients, compared with up to 25% of patients receiving placebo. 4,5 In another study, involving 70 patients with TGN, carbamazepine significantly reduced the severity of pain by 58%, compared with a 26% reduction with placebo (P 0.05). 3 Carbamazepine was subsequently approved by the US Food and Drug Administration (FDA) as a treatment for TGN, and is currently considered to be the drug of choice for TGN. Since then, several AEDs have been shown to produce analgesia in 2003 U.S. Cancer Pain Relief Committee /03/$ see front matter Published by Elsevier. All rights reserved. doi: /s (03)

2 S32 Carrazana and Mikoshiba Vol. 25 No. 5S May 2003 neuropathic pain, and have also proved effective in treating several types of neuropathic pain, including painful diabetic neuropathy and post-herpetic neuralgia. 6 The overlap between the underlying pathophysiologic mechanisms of some epilepsy models and neuropathic pain models supports the rationale for using certain AEDs in the treatment of neuropathic pain. 6,7 Peripheral and central neuroplasticity, such as peripheral overexpression and accumulation of sodium channels at sites of nerve damage, altered activity at central glutamate receptor sites, and increased calcium flux into cells, have been implicated in the pathophysiology of neuropathic pain. Based on their mode of actions, certain AEDs may target peripheral and/or central sensitization mechanisms involved in neuropathic pain. 8 For example, oxcarbazepine (Trileptal, Novartis International AG, Basel, Switzerland), carbamazepine, and phenytoin block sodium channels, thereby reducing the hyperexcitability of damaged peripheral nerves. 7,8 Oxcarbazepine has been shown to inhibit highfrequency firing of nerves without impairing normal impulse conduction. 9 The dual mode of action of oxcarbazepine, modulating both voltage-sensitive sodium channels 10 and highvoltage activated N-type calcium channels, 11 raises the possibility that oxcarbazepine can target certain underlying mechanisms known to be important in the genesis of both peripheral and central sensitization, as discussed in more detail elsewhere in this supplement. Oxcarbazepine Oxcarbazepine is a second-generation AED with proven efficacy as monotherapy and combination therapy in managing partial epileptic seizures, with or without secondary generalization, in adults and children. Head-to-head trials with other first-line AEDs have shown oxcarbazepine to be of comparable efficacy in controlling seizures, while exhibiting a significantly better tolerability profile Fewer patients developed rash or hypersensitivity to oxcarbazepine compared with patients receiving carbamazepine or phenytoin In addition, oxcarbazepine is not associated with serious idiosyncratic hematologic or hepatic effects. For this reason, there is no need for routine monitoring of hematologic and hepatic profiles during treatment with oxcarbazepine. 15,16 Oxcarbazepine also has predictable, linear pharmacokinetics and minimal drug-drug interactions, which facilitate its use as combination therapy, if necessary (Table 1). 15,16 Furthermore, oxcarbazepine does not autoinduce its metabolism; therefore, dose titration and dosage adjustment are relatively simple, and steady-state levels of the drug can be achieved. 15,16 Oxcarbazepine also has a convenient twicedaily dosing regimen and can be taken with or without food, thus facilitating patient compliance. Oxcarbazepine as a Treatment for Neuropathic Pain Clinical Evidence in Trigeminal Neuralgia A series of open-label studies suggest that oxcarbazepine has substantial efficacy in alleviating the pain associated with TGN, with relatively few clinically significant adverse events. 17,18 In most cases, pain relief was noted within hours of receiving oxcarbazepine treatment. In addition, some patients obtained pain relief with oxcarbazepine despite having previously responded poorly (in terms of efficacy or tolerability) to carbamazepine. The first double-blind, crossover trial to evaluate the efficacy of oxcarbazepine ( mg/ day) versus carbamazepine ( mg/ day) reported a comparable analgesic effect between the two treatments, leading to the conclusion that oxcarbazepine offers an alternative to carbamazepine in the treatment of TGN. 19 This finding was confirmed by the results of three subsequent multicenter, doubleblind, randomized trials comparing the efficacy and tolerability of oxcarbazepine versus carbamazepine in patients with newly diagnosed or refractory TGN. 20 Meta-analysis of Table 1 Advantages of Oxcarbazepine Over Carbamazepine in Neuropathic Pain No monitoring of hematologic parameters required Fewer drug-drug interactions No autoinduction of metabolism Comparable efficacy Improved tolerability 27% cross sensitivity with carbamazepine Twice-daily dosing schedule

3 Vol. 25 No. 5S May 2003 Use of Oxcarbazepine in Neuropathic Pain S33 data from these trials showed that oxcarbazepine was as efficacious as carbamazepine in reducing the number of weekly pain attacks (in 88% versus 88% of patients, respectively) and evoked pain (in 58% versus 62% of patients, respectively) (Fig. 1). However, similar to the findings in the epilepsy trials, oxcarbazepine was associated with substantially fewer adverse events than carbamazepine; in particular, there were fewer incidences of vertigo, dizziness, ataxia, and fatigue with oxcarbazepine. Tolerability was reported as good to excellent by 62% of patients receiving oxcarbazepine, compared with 48% of patients receiving carbamazepine. The recommended starting dose for oxcarbazepine treatment in TGN is approximately 600 mg/day (300 mg twice daily), with increases of mg every few days according to the clinical response. In the majority of patients, the effective dose ranges from 600 mg/ day to 1200 mg/day; however, patients with refractory TGN may require doses as high as 2400 mg/day. Fig. 1. Efficacy of oxcarbazepine versus carbamazepine in patients with trigeminal neuralgia (meta-analysis of 3 trials). Reproduced with kind permission. 20 Clinical Evidence in Other Neuropathic Pain Conditions Gabapentin is often used to treat neuropathic pain; however, a substantial proportion of patients find this drug ineffective, partially effective or poorly tolerated. In an open-label study evaluating the efficacy of oxcarbazepine in 18 patients with complex regional pain syndrome refractory to gabapentin treatment, oxcarbazepine ( mg/day) markedly reduced the mean visual analog scale (VAS) score (from 7.4 to 3.3) and the mean McGill Short-Form score (from 28.1 to 9.3), with 33% and 39% of patient responses reported as good and excellent, respectively. 21 Oxcarbazepine was well tolerated, with adverse events (nausea, headache and constipation) reported in only 4 out of 18 (22%) patients. Oxcarbazepine ( mg/day) has also been reported to be effective in a cohort of patients with painful radiculopathy refractory to gabapentin. 22 In total, 15 of 18 (83%) patients reported good to excellent responses following the addition of oxcarbazepine. Significant improvement was seen in patients with symptoms described as burning and allodynia. Overall, oxcarbazepine was well tolerated, with the main adverse events being dizziness, headache, and nausea. A recent open-label trial evaluated the efficacy and tolerability of oxcarbazepine (administered in two dose-escalating phases: up to 900 mg/day in Phase I and up to 1500 mg/day in Phase II), in 12 patients with central pain following spinal cord injury. Seven of the 12 patients in the trial had allodynia. Oxcarbazepine provided moderate pain relief in 58% (7/12) of patients overall, and in 100% (7/7) of the patients with allodynia. Adverse effects were mild and reversible, and included blurred vision, sedation, dizziness, and hyponatremia. The authors suggested that the mechanisms of pain may differ among spinal cord injury patients with and without allodynia. In addition, oxcarbazepine treatment was considered to be beneficial in the treatment of patients with allodynia. 23 Clinical Evidence in Painful Diabetic Neuropathy Data from a limited number of reports have led to the use of carbamazepine in the treatment of painful diabetic neuropathy. For example, carbamazepine (median dose 600 mg/ day) provided moderate-to-complete pain relief in 63% (19/30) of patients with painful diabetic neuropathy, compared with 20% (6/30) of patients receiving placebo (P 0.05). 24 Evidence that oxcarbazepine may also be effective in treating painful diabetic neuropathy is accumulating. Data from an open-label prospective study indicate that oxcarbazepine (mean

4 S34 Carrazana and Mikoshiba Vol. 25 No. 5S May 2003 effective dose 814 mg/day, range mg/ day) may significantly improve pain scores in patients with painful diabetic neuropathy: the VAS score for pain declined from 66.3 at baseline to 34.3 at the end of the trial (P ). 25 Significant improvements were also reported in the McGill total pain score and the Bodily Pain category of the SF-36 Quality of Life questionnaire. Oxcarbazepine was well tolerated, with the most frequent adverse events being similar to those reported in epilepsy studies. In Japan, five studies are currently investigating the efficacy of oxcarbazepine in treating neuropathic pain. In one, an open-label study involving 32 patients with painful diabetic neuropathy, oxcarbazepine (target dose 600 mg/day, following weekly titration from 100 mg/day, through 200 mg/day and 400 mg/day, to 600 mg/day) reduced the mean VAS score from 6.7 cm at baseline to 3.8 cm with 600 mg/day. Another study is a randomized, double-blind, placebocontrolled trial designed to determine the recommended dose of oxcarbazepine (200 mg/ day, 400 mg/day, or 600 mg/day) in Japanese patients with painful diabetic neuropathy. Two hundred and four patients were enrolled in the trial and randomized to the treatment arms. The results indicated a significant improvement in the VAS scores for patients randomized to oxcarbazepine, compared with those randomized to placebo (unpublished data). A large, international clinical development program was also initiated in 2001 to further examine the efficacy and tolerability of oxcarbazepine in neuropathic pain. Five trials are currently underway at study centers across the US, Europe, and Latin America. These include 4 multicenter, double-blind, randomized, placebo-controlled trials involving patients with painful diabetic neuropathy, and one trial involving patients with lumbar radiculopathy. Conclusions Current reports suggest that oxcarbazepine is an effective and well tolerated treatment for neuropathic pain. This efficacy has been noted in a broad range of neuropathic pain conditions, including TGN and painful diabetic neuropathy, and in patients refractory to other AEDs, such as carbamazepine and gabapentin. It is hoped that ongoing large, double-blind, placebo-controlled, clinical trials will confirm the efficacy and tolerability of oxcarbazepine in neuropathic pain. References 1. Bergouignan M. Cures heureuses de nevralgies faciales essentielles par le diphenylhydantoinate de soude. Rev Laryngol Otol Rhinol 1942;63: Blom S. Trigeminal neuralgia: its treatment with a new anticonvulsant drug (G32883). Lancet 1962;1: Campbell FG, Graham JG, Zilkha KJ. Clinical trial of carbamazepine (Tegretol) in trigeminal neuralgia. J Neurol Neurosurg Psychiat 1966;29: Killian JM, Fromm GH. Carbamazepine in the treatment of neuralgia: use and side effects. Arch Neurol 1968;19: Nicol CF. A four year double-blind study of tegretol in facial pain. Headache 1969;9: Jensen TS. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur J Pain 2002; 6(Suppl A): Dickenson AH, Matthews EA, Suzuki R. Neurobiology of neuropathic pain: mode of action of anticonvulsants. Eur J Pain 2002;6(Suppl A): White HS. Comparative anticonvulsant and mechanistic profile of the established and newer antiepileptic drugs. Epilepsia 1999;40(Suppl 5):S2 S Ichikawa K, Koyama N, Kiguchi S, et al. Inhibitory effect of oxcarbazepine on high-frequency firing in peripheral nerve fibers. Eur J Pharmacol 2001;420: McLean MJ, Schmutz M, Wamil AW, et al. Oxcarbazepine: mechanisms of action. Epilepsia 1994; 35(Suppl 3):S5 S Stefani A, Pisani A, De Murtas M, et al. Action of GP 47779, the active metabolite of oxcarbazepine, on the corticostriatal system. II. Modulation of highvoltage-activated calcium currents. Epilepsia 1995; 36: Dam M, Ekberg R, Loyning Y, et al. A doubleblind study comparing oxcarbazepine and carbamazepine in patients with newly diagnosed, previously untreated epilepsy. Epilepsy Res 1989;3: Bill PA, Vigonius U, Pohlmann H, et al. A doubleblind controlled clinical trial of oxcarbazepine versus phenytoin in adults with previously untreated epilepsy. Epilepsy Res 1997;27: Guerreiro MM, Vigonius U, Pohlmann H, et al. A double-blind controlled clinical trial of oxcarbazepine versus phenytoin in children and adolescents with epilepsy. Epilepsy Res 1997;27: Beydoun A, Kutluay E. Oxcarbazepine. Expert Opin Pharmacother 2002;3:59 71.

5 Vol. 25 No. 5S May 2003 Use of Oxcarbazepine in Neuropathic Pain S Lloyd P, Flesch G, Dieterle W. Clinical pharmacology and pharmacokinetics of oxcarbazepine. Epilepsia 1994;35(Suppl 3):S10 S Zakrzewska JM, Patsalos PN. Oxcarbazepine: a new drug in the management of intractable trigeminal neuralgia. J Neurol Neurosurg Psychiatry 1989; 52: Farago F. Trigeminal neuralgia: its treatment with two new carbamazepine analogues. Eur Neurol 1987;26: Lindstrom P. The analgesic effect of carbamazepine in trigeminal neuralgia. Pain 1987;4:S Beydoun A, Schmidt D, D Souza J, on behalf of the Oxcarbazepine Study Group. Meta-analysis of comparative trials of oxcarbazepine versus carbamazepine in trigeminal neuralgia. Poster presented at the 21st American Pain Society Annual Meeting, Baltimore, USA, March Royal M, Bhakta B, Jensen M, et al. An openlabel trial of oxcarbazepine in patients with complex regional pain syndrome refractory to gabapentin. Poster presented at the 17th American Academy of Pain Medicine Annual Meeting, Florida, USA, February Ward S, Royal MA, Jenson M. An open-label trial of oxcarbazepine in patients with radiculopathy refractory to gabapentin. J Pain 2002;3: Jenkins K, Kaplan SE, Leahy LF, et al. Oxcarbazepine in central neuropathic pain with allodynia following spinal cord injury. J Pain 2002;3: Rull JA, Quibrera R, Gonzalez-Milan H, et al. Symptomatic treatment of peripheral diabetic neuropathy with carbamazepine (Tegretol): double blind crossover trial. Diabetologia 1969;5: Carrazana E, Beydoun A, Kobetz S, et al. An open-label, prospective trial of oxcarbazepine for the treatment of painful diabetic neuropathy. Poster presented at the 21st American Pain Society Annual Meeting, Baltimore, USA, March 2002.

Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials

Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials Safety and Efficacy of Oxcarbazepine: Results of Randomized, Double-Blind Trials Ahmad Beydoun, M.D. Oxcarbazepine is approved as monotherapy and adjunctive therapy for partial seizures with and without

More information

PEDIATRIC PHARMACOTHERAPY

PEDIATRIC PHARMACOTHERAPY PEDIATRIC PHARMACOTHERAPY A Monthly Newsletter for Health Care Professionals from the Children s Medical Center at the University of Virginia Volume 7 Number 11 November 2001 A Oxcarbazepine Use in Children

More information

New antiepileptic drugs

New antiepileptic drugs Chapter 29 New antiepileptic drugs J.W. SANDER UCL Institute of Neurology, University College London, National Hospital for Neurology and Neurosurgery, Queen Square, London, and Epilepsy Society, Chalfont

More information

Advice following an Independent Review Panel (IRP)

Advice following an Independent Review Panel (IRP) Scottish Medicines Consortium Advice following an Independent Review Panel (IRP) Pregabalin 25, 50, 75, 100, 150, 200 and 300mg capsules (Lyrica ) Pfizer No. 157/05 7 July 2006 The Scottish Medicines Consortium

More information

Lacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011

Lacosamide (Vimpat) for partial-onset epilepsy monotherapy. December 2011 Lacosamide (Vimpat) for partial-onset epilepsy monotherapy This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a

More information

Efficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials

Efficacy of Levetiracetam: A Review of Three Pivotal Clinical Trials Epilepsia, 42(Suppl. 4):31 35, 2001 Blackwell Science, Inc. International League Against Epilepsy Efficacy of : A Review of Three Pivotal Clinical Trials Michael Privitera University of Cincinnati Medical

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium pregabalin, 25mg, 50mg, 75mg, 100mg, 150mg, 200mg, 225mg, 300mg capsules (Lyrica ) No. (389/07) Pfizer Limited 6 July 2007 The Scottish Medicines Consortium has completed

More information

MONOTHERAPY IS PREferred

MONOTHERAPY IS PREferred Monotherapy in Epilepsy Role of the Newer Antiepileptic Drugs Blanca Vazquez, MD NEUROLOGICAL REVIEW Background: Monotherapy is the goal for pharmacological treatment of epilepsy. Well-controlled trials

More information

Double-blind, placebo controlled, crossover study

Double-blind, placebo controlled, crossover study 448 48ournal of Neurology, Neurosurgery, and Psychiatry 1993;56:448-453 PAPERS Department of Clinical Pharmacology, Queen Elizabeth Hospital, Woodville, SA, G J Schapel Liverpool Hospital, Liverpool, NSW,

More information

5.9. Rehabilitation to Improve Central Pain

5.9. Rehabilitation to Improve Central Pain 5.9. Rehabilitation to Improve Central Pain Evidence Tables and References Canadian Best Practice Recommendations for Stroke Care 2011-2013 Update Last Updated: June 25 th, 2013 Contents Search Strategy...

More information

Medications for the Treatment of Neuropathic Pain

Medications for the Treatment of Neuropathic Pain Medications for the Treatment of Neuropathic Pain February 23, 2011 Jinny Tavee, MD Associate Professor Neurological Institute Cleveland Clinic Foundation Neuropathic Pain Pain, paresthesias, and sensory

More information

CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Stroke Rehabilitation Evidence Tables Rehabilitation to Improve Central Pain

CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS. Stroke Rehabilitation Evidence Tables Rehabilitation to Improve Central Pain CANADIAN STROKE BEST PRACTICE RECOMMENDATIONS Rehabilitation to Improve Central Pain Hebert, D, Teasell, R (Writing Group Chairs) on Behalf of the STROKE REHABILITATION Writing Group 2015 December 2015

More information

eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd

eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd eslicarbazepine acetate 800mg tablet (Zebinix) SMC No. (592/09) Eisai Ltd 8 October 2010 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards

More information

Refractory epilepsy: treatment with new antiepileptic drugs

Refractory epilepsy: treatment with new antiepileptic drugs Seizure 2000; 9: 51 57 doi: 10.1053/seiz.1999.0348, available online at http://www.idealibrary.com on Refractory epilepsy: treatment with new antiepileptic drugs P. K. DATTA & P. M. CRAWFORD Department

More information

IF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE?

IF I M NOT TREATING WITH OPIOIDS, THEN WHAT AM I SUPPOSED TO USE? NON-OPIOID TREATMENT OPTIONS FOR CHRONIC PAIN Alison Knutson, PharmD, BCACP Medication Management Pharmacist Park Nicollet Creekside Clinic Dr. Knutson indicated no potential conflict of interest to this

More information

Medications for Epilepsy What I Need to Know

Medications for Epilepsy What I Need to Know Medications for Epilepsy What I Need to Know Safiya Ladak, BSc.Phm. Toronto Western Hospital, UHN Clinical Pharmacist, Neurology and Neurosurgery June 4, 2016 Learning Objectives Treatment options for

More information

MorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients

MorphiDex (MS:DM) Double-Blind, Multiple-Dose Studies In Chronic Pain Patients Vol. 19 No. 1(Suppl.) January 2000 Journal of Pain and Symptom Management S37 Proceedings Supplement NMDA-Receptor Antagonists: Evolving Role in Analgesia MorphiDex (MS:DM) Double-Blind, Multiple-Dose

More information

Introduction. 1 person in 20 will have an epileptic seizure at some time in their life

Introduction. 1 person in 20 will have an epileptic seizure at some time in their life Introduction 1 person in 20 will have an epileptic seizure at some time in their life Epilepsy is diagnosed on the basis of two or more epileptic seizures. Around 450,000 people in the UK have epilepsy

More information

2018 American Academy of Neurology

2018 American Academy of Neurology Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs I: Treatment of New-Onset Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of

More information

Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation).

Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). TITLE OF THE THESIS / RESEARCH: Modified release drug delivery system for antiepileptic drug (Formulation development and evaluation). INTRODUCTION: Epilepsy is a common chronic neurological disorder characterized

More information

When choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E.

When choosing an antiepileptic ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs. Based on a presentation by Barry E. ... PRESENTATION... Pharmacokinetics of the New Antiepileptic Drugs Based on a presentation by Barry E. Gidal, PharmD Presentation Summary A physician s choice of an antiepileptic drug (AED) usually depends

More information

MEDICAL POLICY SUBJECT: KETAMINE INFUSION THERAPY FOR THE TREATMENT OF CHRONIC PAIN SYNDROMES POLICY NUMBER: CATEGORY: Technology Assessment

MEDICAL POLICY SUBJECT: KETAMINE INFUSION THERAPY FOR THE TREATMENT OF CHRONIC PAIN SYNDROMES POLICY NUMBER: CATEGORY: Technology Assessment Clinical criteria used to make utilization review decisions are based on credible scientific evidence published in peer reviewed medical literature generally recognized by the medical community. Guidelines

More information

Peripheral Subcutaneous Field Stimulation

Peripheral Subcutaneous Field Stimulation Peripheral Subcutaneous Field Stimulation Policy Number: 7.01.139 Last Review: 9/2014 Origination: 7/2013 Next Review: 1/2015 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide

More information

Lyrica. Lyrica, Lyrica CR (pregabalin) Description

Lyrica. Lyrica, Lyrica CR (pregabalin) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.18 Subject: Page: 1 of 7 Last Review Date: March 16, 2018 Description, CR (pregabalin) Background

More information

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT NOVEMBER 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Sciatic Pain

More information

Classification of Facial Pain. Surgical Treatment of Facial Pain. Typical trigeminal neuralgia. Atypical trigeminal neuralgia

Classification of Facial Pain. Surgical Treatment of Facial Pain. Typical trigeminal neuralgia. Atypical trigeminal neuralgia Surgical Treatment of Facial Pain Nicholas M. Barbaro, MD University of California at San Francisco Classification of Facial Pain Trigeminal neuralgia Atypical trigeminal neuralgia Neuropathic facial pain

More information

Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine

Concomitant administration of rifampicin and oxcarbazepine results in a significant decrease of the active MHD metabolite of oxcarbazepine Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2016 Concomitant administration of rifampicin and oxcarbazepine results in

More information

Epilepsy and EEG in Clinical Practice

Epilepsy and EEG in Clinical Practice Mayo School of Professional Development Epilepsy and EEG in Clinical Practice November 10-12, 2016 Hard Rock Hotel at Universal Orlando Orlando, FL Course Directors Jeffrey Britton, MD and William Tatum,

More information

Zonisamide for migraine prophylaxis in refractory patients

Zonisamide for migraine prophylaxis in refractory patients Thomas Jefferson University Jefferson Digital Commons Department of Neurology Faculty Papers Department of Neurology March 2006 Zonisamide for migraine prophylaxis in refractory patients Avi Ashkenazi

More information

An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine

An open-label pilot study on the efficacy and tolerability of levetiracetam in the prophylaxis of migraine J Headache Pain () :9 9 DOI 1.1/s119--- RAPID COMMUNICATION Virgilio Gallai Andrea Alberti Cristiana Rossi Francesca Coppola Beatrice Gallai Giovanni Mazzotta Paola Sarchielli An open-label pilot study

More information

Drug Monograph-Oxcarbazepine

Drug Monograph-Oxcarbazepine Drug Monograph Generic name: Oxcarbazepine Brand name: Trileptal Manufacturer: Norvatis (www.norvatis.com) Classification: Anti-epileptic drug Similar agents: Carbamazepine Summary Oxcarbazepine is a new

More information

levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd

levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd Scottish Medicines Consortium Resubmission levetiracetam 250,500,750 and 1000mg tablets and levetiracetam oral solution 100mg/1ml (Keppra ) (No. 397/07) UCB Pharma Ltd 11 January 2008 The Scottish Medicines

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium duloxetine 30mg and 60mg capsules (Cymbalta ) No. (285/06) Eli Lilly and Company Limited/Boehringer Ingelheim 4 August 2006 The Scottish Medicines Consortium has completed

More information

Peripheral Subcutaneous Field Stimulation. Description

Peripheral Subcutaneous Field Stimulation. Description Subject: Peripheral Subcutaneous Field Stimulation Page: 1 of 6 Last Review Status/Date: June 2016 Peripheral Subcutaneous Field Stimulation Description Peripheral subcutaneous field stimulation (PSFS,

More information

Lyrica. Lyrica (pregabalin) Description

Lyrica. Lyrica (pregabalin) Description Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.18 Subject: Lyrica Page: 1 of 6 Last Review Date: June 22, 2017 Lyrica Description Lyrica (pregabalin)

More information

New Medicines Profile

New Medicines Profile New Medicines Profile February 2010 Issue No. 10/02 Eslicarbazepine Concise evaluated information to support the managed entry of new medicines in the NHS Brand Name, (Manufacturer): Zebinix (Eisai Limited)

More information

OXCARBAZEPINE. THERAPEUTICS Brands Trileptal see index for additional brand names. Generic? Yes

OXCARBAZEPINE. THERAPEUTICS Brands Trileptal see index for additional brand names. Generic? Yes OXCARBAZEPINE THERAPEUTICS Brands Trileptal see index for additional brand names Generic? Yes Class Anticonvulsant, voltage-sensitive sodium channel antagonist Commonly Prescribed for (bold for FDA approved)

More information

K30 case study: innovative treatment approach to myofascial neck pain. Marc Brodsky, MD UCLA Center for East-West Medicine May 27, 2008

K30 case study: innovative treatment approach to myofascial neck pain. Marc Brodsky, MD UCLA Center for East-West Medicine May 27, 2008 K30 case study: innovative treatment approach to myofascial neck pain Marc Brodsky, MD UCLA Center for East-West Medicine May 27, 2008 Patient presentation 24 yo female medical student with a oneyear h/o

More information

ZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide

ZONISAMIDE THERAPEUTICS. Brands * Zonegran. Generic? Not in US. If It Doesn t Work * Class Antiepileptic drug (AED), structurally a sulfonamide Z:/3-PAGINATION/SBT/2-PROOFS/NWMS/9780521136723C111//9780521136723C111.3D 376 [376 380] ZONISAMIDE Brands Zonegran Generic? Not in US THERAPEUTICS Class Antiepileptic drug (AED), structurally a sulfonamide

More information

No May 25, Eisai Co., Ltd.

No May 25, Eisai Co., Ltd. No.16-35 May 25, 2016 Eisai Co., Ltd. EISAI TO LAUNCH IN-HOUSE DEVELOPED ANTIEPILEPTIC DRUG FYCOMPA (PERAMPANEL HYDRATE) AS ADJUNCTIVE THERAPY FOR PARTIAL-ONSET AND GENERALIZED TONIC-CLONIC SEIZURES IN

More information

Drug Use Evaluation: Newer Antiepileptic Drugs Executive Summary

Drug Use Evaluation: Newer Antiepileptic Drugs Executive Summary Drug Use Research & Management Program Oregon State University, 3303 SW Bond Av CH12C, Portland, Oregon 97239 4501 Phone 503 494 9954 Fax 503 494 1082 Drug Use Evaluation: Newer Antiepileptic Drugs Executive

More information

Difficult to treat childhood epilepsy: Lessons from clinical case scenario

Difficult to treat childhood epilepsy: Lessons from clinical case scenario Difficult to treat childhood epilepsy: Lessons from clinical case scenario Surachai Likasitwattanakul, M.D. Department of Pediatrics Faculty of Medicine, Siriraj Hospital Natural history of Epilepsy Untreated

More information

Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am

Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Treatment of Neuropathic Pain: What Does the Evidence Say? or Just the Facts Ma am Tim R Brown, PharmD, BCACP, FASHP Director of Clinical Pharmacotherapy Cleveland Clinic Akron General Center for Family

More information

2018 American Academy of Neurology

2018 American Academy of Neurology Practice Guideline Update Efficacy and Tolerability of the New Antiepileptic Drugs II: Treatment-Resistant Epilepsy Report by: Guideline Development, Dissemination, and Implementation Subcommittee of the

More information

ANTIEPILEPTIC DRUGS FOR CHRONIC NEUROPATHIC PAIN

ANTIEPILEPTIC DRUGS FOR CHRONIC NEUROPATHIC PAIN ANTIEPILEPTIC DRUGS FOR CHRONIC NEUROPATHIC PAIN MED-3950, 5-årsoppgaven Profesjonsstudiet i medisin ved Universitetet i Tromsø Student: Anders Joakim Lagerlöf MK 10 Veiledere: Lena Danielsson & Nils Kolstrup

More information

In clinical studies, gabapentin efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day (1-3).

In clinical studies, gabapentin efficacy was demonstrated over a range of doses from 1800 mg/day to 3600 mg/day (1-3). Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.75.17 Subject: Gabapentin Page: 1 of 6 Last Review Date: June 22, 2017 Gabapentin Description Gabapentin

More information

LYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS

LYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS Volume 20, Issue 7 April 2005 LYRICA FOR THE TREATMENT OF NEUROPATHIC PAIN DISORDERS Tanja Lepir, Pharm.D. Candidate Nervous system dysfunction leading to neuropathic pain can occur from many causes: infection,

More information

When to start, which drugs and when to stop

When to start, which drugs and when to stop When to start, which drugs and when to stop Dr. Suthida Yenjun, MD. PMK Epilepsy Annual Meeting 2016 The main factors to consider in making the decision The risk for recurrent seizures, which varies based

More information

National Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007

National Horizon Scanning Centre. Pregabalin (Lyrica) for fibromyalgia. September 2007 Pregabalin (Lyrica) for fibromyalgia September 2007 This technology summary is based on information available at the time of research and a limited literature search. It is not intended to be a definitive

More information

REFRACTORY TRIGEMINAL NEURALGIA: IS BOTULINUM THE ANSWER? By: Amanda Fontes. Home for the Summer Program May to August Pine Falls, Manitoba

REFRACTORY TRIGEMINAL NEURALGIA: IS BOTULINUM THE ANSWER? By: Amanda Fontes. Home for the Summer Program May to August Pine Falls, Manitoba By: Amanda Fontes Home for the Summer Program May to August 2017 Pine Falls, Manitoba Supervisors: Dr. Ali and Dr. Ota Abstract: Patient Case: The diagnosis of classical trigeminal neuralgia was made in

More information

New generation anti-epileptics for facial pain and headache

New generation anti-epileptics for facial pain and headache Acta neurol. belg., 2001, 101, 42-46 New generation anti-epileptics for facial pain and headache Valérie DELVAUX and Jean SCHOENEN University Department of Neurology, University of Liège, Liège, Belgium

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: (Lyrica) Reference Number: ERX.NPA.10 Effective Date: 06.01.15 Last Review Date: 08.17 Line of Business: Commercial [Prescription Drug Plan] Revision Log See Important Reminder at the

More information

GABAPENTIN BNF Gabapentin is a chemical analogue of γ-aminobutyric acid (GABA) but does not act

GABAPENTIN BNF Gabapentin is a chemical analogue of γ-aminobutyric acid (GABA) but does not act GABAPENTIN BNF 4.8.1 Class: Anti-epileptic. Indications: Adjunctive treatment for partial seizures with or without secondary generalisation; 1,2 neuropathic pain of any cause. 3 12 Pharmacology Gabapentin

More information

TRANSPARENCY COMMITTEE OPINION. 19 July 2006

TRANSPARENCY COMMITTEE OPINION. 19 July 2006 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 19 July 2006 Keppra 250 mg, film-coated tablets Box of 60 tablets (CIP code: 356 013-6) Keppra 500 mg, film-coated

More information

Peripheral Subcutaneous Field Stimulation

Peripheral Subcutaneous Field Stimulation Peripheral Subcutaneous Field Stimulation Policy Number: 7.01.139 Last Review: 3/2018 Origination: 7/2013 Next Review: 9/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will not provide

More information

Neuropathic Pain in Palliative Care

Neuropathic Pain in Palliative Care Neuropathic Pain in Palliative Care Neuropathic Pain in Advanced Cancer Affects 40% of patients Multiple concurrent pains are common Often complex pathophysiology with mixed components Nocioceptive Neuropathic

More information

Scottish Medicines Consortium

Scottish Medicines Consortium Scottish Medicines Consortium levetiracetam, 250, 500, 750 and 1000mg tablets and levetiracetam oral solution 100mg/ml (Keppra ) No. (394/07) UCB Pharma Limited 10 August 2007 The Scottish Medicines Consortium

More information

Non-opioid and adjuvant pain management

Non-opioid and adjuvant pain management Non-opioid and adjuvant pain management ALLISON JORDAN, MD, HMDC MEDICAL DIRECTOR OF PALLIATIVE CARE SERVICES CHRISTIAN AND ALTON MEMORIAL HOSPITALS ASSOCIATE MEDICAL DIRECTOR, BJC HOSPICE ASSISTANT PROFESSOR

More information

Disclosure. Learning Objectives

Disclosure. Learning Objectives Linda D. Leary, M.D. Associate Clinical Professor of Pediatrics & Neurology South Texas Comprehensive Epilepsy Center UT Health Science Center San Antonio Disclosure Linda D. Leary, M.D. discloses the

More information

Overview of Neuropathic pain

Overview of Neuropathic pain Overview of Neuropathic pain Kongkiat Kulkantrakorn,M.D. Neurology division Thammasat University 1 Contents Overview of pain New concepts and mechanism Treatment options New data in management 2 3 Breaking

More information

Medical Policy Manual. Topic: Peripheral Subcutaneous Field Stimulation Date of Origin: April Section: Surgery Last Reviewed Date: April 2014

Medical Policy Manual. Topic: Peripheral Subcutaneous Field Stimulation Date of Origin: April Section: Surgery Last Reviewed Date: April 2014 Medical Policy Manual Topic: Peripheral Subcutaneous Field Stimulation Date of Origin: April 2013 Section: Surgery Last Reviewed Date: April 2014 Policy No: 188 Effective Date: July 1, 2014 IMPORTANT REMINDER

More information

New drugs necessity for therapeutic drug monitoring

New drugs necessity for therapeutic drug monitoring New drugs necessity for therapeutic drug monitoring Stephan Krähenbühl Clinical Pharmacology & Toxicology University Hospital Basel kraehenbuehl@uhbs.ch Drugs suitable for TDM Narrow therapeutic range

More information

Types of epilepsy. 1)Generalized type: seizure activity involve the whole brain, it is divided into:

Types of epilepsy. 1)Generalized type: seizure activity involve the whole brain, it is divided into: Types of epilepsy We have different types of epilepsy, so it is not one type of seizures that the patient can suffer from; we can find some patients with generalized or partial seizure. So, there are two

More information

Ninlaro. (ixazomib) New Product Slideshow

Ninlaro. (ixazomib) New Product Slideshow Ninlaro (ixazomib) New Product Slideshow Introduction Brand name: Ninlaro Generic name: Ixazomib Pharmacological class: Proteasome inhibitor Strength and Formulation: 2.3mg, 3mg, 4mg; gel caps Manufacturer:

More information

Seizure: the clinical manifestation of an abnormal and excessive excitation and synchronization of a population of cortical

Seizure: the clinical manifestation of an abnormal and excessive excitation and synchronization of a population of cortical Are There Sharing Mechanisms of Epilepsy, Migraine and Neuropathic Pain? Chin-Wei Huang, MD, PhD Department of Neurology, NCKUH Basic mechanisms underlying seizures and epilepsy Seizure: the clinical manifestation

More information

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT

NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING FOR PAIN MANAGEMENT DECENBER 2011 NORLAND AVENUE PHARMACY PRESCRIPTION COMPOUNDING N ORLANDA VENUEP HARMACY. COM We customize individual prescriptions for the specific needs of our patients. INSIDE THIS ISSUE: Trigeminal

More information

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist

More information

Neuropathic Pain Treatment Guidelines

Neuropathic Pain Treatment Guidelines Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,

More information

PFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999

PFIZER INC. Study Initiation Date and Primary Completion or Completion Dates: 11 November 1998 to 17 September 1999 PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. For publications based on this study, see associated bibliography.

More information

I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs)

I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) 1 2 I. Introduction Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity

More information

Opinion 24 July 2013

Opinion 24 July 2013 The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 24 July 2013 FYCOMPA 2 mg, film-coated tablet B/7 (CIP: 34009 267 760 0 8) B/28 (CIP: 34009 268 447 4 5) FYCOMPA 4

More information

Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data

Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data Elmer ress Short Communication J Neurol Res. 2015;5(4-5):252-256 Somnolence and Sedation Were Transient Adverse Events for Most Patients Receiving Clobazam Therapy: Post Hoc Analysis of Trial OV-1012 Data

More information

Tegretol and low sodium levels

Tegretol and low sodium levels Tegretol and low sodium levels Gogamz Menu 7-2-2018 Easy to read patient leaflet for Tegretol. If you have taken certain drugs used for low mood. Signs of low sodium levels like headache,. Trigeminal Neuralgia

More information

LMMG New Medicine Recommendation

LMMG New Medicine Recommendation LMMG New Medicine Recommendation Oxcarbazepine (Trileptal ) for the treatment of epilepsy LMMG Recommendation: Amber 0: Oxcarbazepine (Trileptal ) is recommended for use as monotherapy or adjunctive therapy

More information

Gabapentin vs. Amitriptyline in Painful Diabetic Neuropathy: An Open-Label Pilot Study

Gabapentin vs. Amitriptyline in Painful Diabetic Neuropathy: An Open-Label Pilot Study 280 Journal of Pain and Symptom Management Vol. 20 No. 4 October 2000 Original Article Gabapentin vs. Amitriptyline in Painful Diabetic Neuropathy: An Open-Label Pilot Study Carlo Dallocchio, MD, Carlo

More information

Brian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD

Brian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD Brian Kahan, D.O. FAAPMR, DABPM, DAOCRM, FIPP Center for Pain Medicine and Physiatric Rehabilitation 2002 Medical Parkway Suite 150 Annapolis, MD 1630 Main Street Suite 215 Chester, MD 410-571-9000 www.4-no-pain.com

More information

MEDICAL POLICY. SUBJECT: KETAMINE INFUSION THERAPY FOR THE TREATMENT OF CHRONIC PAIN SYNDROMES POLICY NUMBER: CATEGORY: Technology Assessment

MEDICAL POLICY. SUBJECT: KETAMINE INFUSION THERAPY FOR THE TREATMENT OF CHRONIC PAIN SYNDROMES POLICY NUMBER: CATEGORY: Technology Assessment MEDICAL POLICY PAGE: 1 OF: 5 If the member's subscriber contract excludes coverage for a specific service it is not covered under that contract. In such cases, medical policy criteria are not applied.

More information

CLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice?

CLINICIAN INTERVIEW AS i M: When you examine a clinical trial in new- onset epilepsy, how relevant are the results to your daily clinical practice? FROM CLINICAL TRIALS TO CLINICAL PRACTICE: TRANSLATING EPILEPSY RESEARCH INTO PATIENT CARE Interview with Jacqueline A. French, MD Dr Jacqueline A. French is a Professor in the Department of Neurology

More information

Selection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy

Selection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy Selection of Anti-Epileptic Medication in Newly Diagnosed Epilepsy S Venkataraman *, CS Narayanan ** * Senior Consultant Neurologist, Mata Chanan Devi Hospital, New Delhi; ** Classified Specialist (Medicine

More information

Drug Class Review. Long-Acting Opioid Analgesics

Drug Class Review. Long-Acting Opioid Analgesics Drug Class Review Long-Acting Opioid Analgesics Final Update 5 Report April 2008 The purpose of reports is to make available information regarding the comparative clinical effectiveness and harms of different

More information

Anticonvulsants Antiseizure

Anticonvulsants Antiseizure Anticonvulsants Antiseizure Seizure disorders Head trauma Stroke Drugs (overdose, withdrawal) Brain tumor Encephalitis/ Meningitis High fever Hypoglycemia Hypocalcemia Hypoxia genetic factors Epileptic

More information

Curriculum Vitae, Edward H. Ortiz, M.D.

Curriculum Vitae, Edward H. Ortiz, M.D. CONTACT INFORMATION: Site Selection and Information: Bobbie Theodore, Alliance Director Tel. (916) 939-6696 Fax (208) 575-3169 Email: clinicaltrials@alliancesites.com AFFILIATIONS: FutureSearch Trials

More information

New AEDs in Uncontrolled seizures

New AEDs in Uncontrolled seizures New AEDs in Uncontrolled seizures Uncontrolled seizures/epilepsy Intractable epilepsy, Refractory epilepsy, Pharmacoresistant epilepsy Dr. Suthida Yenjun Traditionally, referred to therapeutic failure

More information

TIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes

TIAGABINE. THERAPEUTICS Brands Gabitril see index for additional brand names. Generic? Yes TIAGABINE THERAPEUTICS Brands Gabitril see index for additional brand names Generic? Yes Class Anticonvulsant; selective GABA reuptake inhibitor (SGRI) Commonly Prescribed for (bold for FDA approved) Partial

More information

2. SYNOPSIS Name of Sponsor/Company:

2. SYNOPSIS Name of Sponsor/Company: in patients with refractory partial seizures 14 Jun 2007 2. SYNOPSIS TITLE OF STUDY: Efficacy and safety of BIA 2-093 as adjunctive therapy for refractory partial seizures in a double-blind, randomized,

More information

Unit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders

Unit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders Unit VIII Problem 7 Pharmacology: Principles of Management of Seizure Disorders - Terminologies: Anti-convulsants: they are used to control convulsions seen in certain types of epilepsy. Convulsions may

More information

Review of health related quality of life evidence in the TLoC population

Review of health related quality of life evidence in the TLoC population Appendix H Review of health related quality of life evidence in the TLoC population The aim of this review is to summarise the available evidence on healthrelated quality of life (HRQoL) that could be

More information

Supernus Pharmaceuticals

Supernus Pharmaceuticals Supernus Pharmaceuticals Investor Presentation March 2017 1 Safe Harbor Statement This presentation and other matters discussed today or answers that may be given to questions asked include forward-looking

More information

7 th November % of patients had lidocaine plasters prescribed for the licensed indication of post herpatic neuralgia

7 th November % of patients had lidocaine plasters prescribed for the licensed indication of post herpatic neuralgia Directorate of Integrated Care Health and Social Care Board 12-22 Linenhall Street Belfast BT2 8BS Tel : 028 90553782 Fax : 028 90553622 Web Site: www.hscboard.hscni.net 7 th November 2013 Dear colleague

More information

Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy

Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy Special Article Efficacy and tolerability of the new antiepileptic drugs II: Treatment of refractory epilepsy Report of the Therapeutics and Technology Assessment Subcommittee and Quality Standards Subcommittee

More information

improving the patient s quality of life.

improving the patient s quality of life. Epilepsy is the tendency to have recurrent seizures unprovoked by systemic or acute neurologic insults. Antiepileptic drugs (AEDs) are those which decrease the frequency and/or severity of seizures in

More information

Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study

Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study Q J Med 25; 98:29 34 doi:1.193/qjmed/hci5 Divalproex sodium in the management of post-herpetic neuralgia: a randomized double-blind placebo-controlled study D.K. KOCHAR, P. GARG, R.A. BUMB, S.K. KOCHAR,

More information

Shared Care Guidance. Vigabatrin

Shared Care Guidance. Vigabatrin North of Tyne Area Prescribing Committee Shared Care Guidance Vigabatrin July 2014 (Review date July 2016) This guidance has been prepared and approved for use in Newcastle, North Tyneside and Northumberland.

More information

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES

NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES NEUROPATHIC CANCER PAIN STANDARDS AND GUIDELINES GENERAL PRINCIPLES Neuropathic pain may be relieved in the majority of patients by multimodal management A careful history and examination are essential.

More information

Safety and Efficacy Review: Lacosamide for the Treatment of Diabetic Neuropathic Pain

Safety and Efficacy Review: Lacosamide for the Treatment of Diabetic Neuropathic Pain Clinical Medicine Insights: Therapeutics Review Open Access Full open access to this and thousands of other papers at http://www.la-press.com. Safety and Efficacy Review: Lacosamide for the Treatment of

More information

Epilepsy characterized by recurrent and unprovoked

Epilepsy characterized by recurrent and unprovoked Literature Review New Antiepileptic Agents Linda P. Nelson, DMD, MScD Ilse Savelli-Castillo, DDS Dr. Nelson is associate in dentistry, Department of Pediatric Dentistry, Children s Hospital, and is assistant

More information

Summary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin)

Summary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin) EMA/247834/2014 Summary of the risk management plan (RMP) for Pregabalin Pfizer (pregabalin) Overview of disease epidemiology Epilepsy Epilepsy is a long-term condition affecting the brain and is characterised

More information

A Phase II Study to Establish the Efficacy and Toxicity of Sodium Valproate in Patients With Cancer-Related Neuropathic Pain

A Phase II Study to Establish the Efficacy and Toxicity of Sodium Valproate in Patients With Cancer-Related Neuropathic Pain 204 Journal of Pain and Symptom Management Vol. 21 No. 3 March 2001 Original Article A Phase II Study to Establish the Efficacy and Toxicity of Sodium Valproate in Patients With Cancer-Related Neuropathic

More information

From Gold Beads to Keppra: Update on Anticonvulsant Therapy

From Gold Beads to Keppra: Update on Anticonvulsant Therapy From Gold Beads to Keppra: Update on Anticonvulsant Therapy Dr. Gregg Kortz, DVM, Diplomate ACVIM (Neurology) The search for effective antiepileptic drugs began over 2000 years ago. Over the centuries,

More information